$27.33
1.365.24%
Last update: 11:36 AM
15 minutes delayed
Comments
Loading...
Myriad Genetics
MYGNNASDAQ
Myriad Genetics (NASDAQ:MYGN) Stock, Analyst Ratings, Price Targets, Forecasts
Myriad Genetics Inc has a consensus price target of $25.09 based on the ratings of 12 analysts. The high is $35 issued by Leerink Partners on May 8, 2024. The low is $14 issued by JP Morgan on November 7, 2023. The 3 most-recent analyst ratings were released by Scotiabank, Jefferies, and Piper Sandler on June 27, 2024, June 3, 2024, and May 13, 2024, respectively. With an average price target of $25.67 between Scotiabank, Jefferies, and Piper Sandler, there's an implied -6.09% downside for Myriad Genetics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Jefferies
Piper Sandler
Leerink Partners
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Myriad Genetics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 6.11% | Scotiabank | Sung Ji Nam | → $29 | Initiates | → Sector Outperform | Get Alert |
| 06/03/2024 | Buy Now | -26.82% | Jefferies | Tycho Peterson | $25 → $20 | Assumes | Hold → Underperform | Get Alert |
| 05/13/2024 | Buy Now | 2.45% | Piper Sandler | John Peterson | $23 → $28 | Maintains | Neutral | Get Alert |
| 05/08/2024 | Buy Now | 28.06% | Leerink Partners | Puneet Souda | $25 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 13.43% | Goldman Sachs | Matthew Sykes | $28 → $31 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 13.43% | Goldman Sachs | Matthew Sykes | $28 → $31 | Maintains | Buy | Get Alert |
| 12/21/2023 | Buy Now | -15.84% | Piper Sandler | John Peterson | → $23 | Initiates | → Neutral | Get Alert |
| 12/19/2023 | Buy Now | -26.82% | Wells Fargo | Timothy Daley | → $20 | Initiates | → Equal-Weight | Get Alert |
| 12/14/2023 | Buy Now | -15.84% | Guggenheim | Subbu Nambi | → $23 | Initiates | → Buy | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel | — | Initiates | → Outperform | Get Alert |
| 11/07/2023 | Buy Now | -48.77% | JP Morgan | Rachel Vatnsdal | $17 → $14 | Maintains | Underweight | Get Alert |
| 08/07/2023 | Buy Now | -37.8% | JP Morgan | Rachel Vatnsdal | $18 → $17 | Maintains | Underweight | Get Alert |
| 07/24/2023 | Buy Now | 2.45% | Goldman Sachs | Matthew Sykes | $25 → $28 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | 2.45% | Goldman Sachs | Matthew Sykes | $25 → $28 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | -8.53% | Goldman Sachs | Matthew Sykes | $18 → $25 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | -8.53% | Goldman Sachs | Matthew Sykes | $18 → $25 | Upgrade | Sell → Buy | Get Alert |
| 05/04/2023 | Buy Now | -34.14% | Goldman Sachs | Matthew Sykes | $20 → $18 | Maintains | Sell | Get Alert |
| 05/04/2023 | Buy Now | -12.18% | Stephens & Co. | Mason Carrico | → $24 | Reiterates | → Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | -12.18% | Stephens & Co. | Mason Carrico | $17 → $24 | Maintains | Equal-Weight | Get Alert |
| 03/03/2023 | Buy Now | -1.21% | Raymond James | Andrew Cooper | $25 → $27 | Maintains | Outperform | Get Alert |
| 01/18/2023 | Buy Now | -8.53% | Raymond James | Andrew Cooper | → $25 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/02/2022 | Buy Now | -8.53% | SVB Leerink | Puneet Souda | $27 → $25 | Maintains | Market Perform | Get Alert |
| 10/06/2022 | Buy Now | -19.5% | Stephens & Co. | Mason Carrico | → $22 | Initiates | → Equal-Weight | Get Alert |
| 08/05/2022 | Buy Now | 9.77% | SVB Leerink | Puneet Souda | $26 → $30 | Maintains | Market Perform | Get Alert |
| 05/05/2022 | Buy Now | -4.87% | SVB Leerink | Puneet Souda | $29 → $26 | Maintains | Market Perform | Get Alert |
| 04/19/2022 | Buy Now | -15.84% | Goldman Sachs | Matthew Sykes | $26 → $23 | Maintains | Sell | Get Alert |
| 11/03/2021 | Buy Now | 28.06% | SVB Leerink | Puneet Souda | — | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Myriad Genetics (MYGN) stock?
The latest price target for Myriad Genetics (NASDAQ:MYGN) was reported by Scotiabank on June 27, 2024. The analyst firm set a price target for $29.00 expecting MYGN to rise to within 12 months (a possible 6.11% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Myriad Genetics (MYGN)?
The latest analyst rating for Myriad Genetics (NASDAQ:MYGN) was provided by Scotiabank, and Myriad Genetics initiated their sector outperform rating.
When was the last upgrade for Myriad Genetics (MYGN)?
The last upgrade for Myriad Genetics Inc happened on May 8, 2024 when Leerink Partners raised their price target to $35. Leerink Partners previously had a market perform for Myriad Genetics Inc.
When was the last downgrade for Myriad Genetics (MYGN)?
There is no last downgrade for Myriad Genetics.
When is the next analyst rating going to be posted or updated for Myriad Genetics (MYGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Myriad Genetics (MYGN) correct?
While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a initiated with a price target of $0.00 to $29.00. The current price Myriad Genetics (MYGN) is trading at is $27.33, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.